Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 4
2014 5
2016 4
2017 8
2018 5
2019 6
2020 9
2021 9
2022 5
2023 7
2024 3
2025 6
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
Fayette J, Licitra L, Harrington K, Haddad R, Siu LL, Liu YC, Tahara M, Machiels JP, Rischin D, Seiwert TY, Ferris RL, Keilholz U, Psyrri A, Keam B, Bossi P, Metcalf R, Hsieh CY, Clement PMJ, Isaev P, Mudunov A, Dinis J, Hoeben A, Kasper S, Klinghammer K, Hwang M, Blando J, Serrano O, Ruscica D, Cohen RB; INTERLINK-1 investigators. Fayette J, et al. Clin Cancer Res. 2025 Jul 1;31(13):2617-2627. doi: 10.1158/1078-0432.CCR-25-0073. Clin Cancer Res. 2025. PMID: 40300079 Free PMC article. Clinical Trial.
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Haddad RI, et al. Among authors: daste a. J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6. J Clin Oncol. 2023. PMID: 36473143 Free PMC article. Clinical Trial.
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial.
Bourhis J, Aupérin A, Borel C, Lefebvre G, Racadot S, Geoffrois L, Sun XS, Saada E, Cirauqui B, Rutkowski T, Henry S, Modesto A, Johnson A, Chapet S, Calderon B, Sire C, Malard O, Bainaud M, Da Silva Motta A, Thureau S, Pointreau Y, Blanchard P, Buiret G, Bozec L, Lopez S, Vanbockstael J, Bosset M, Greilsamer C, Daste A, Bruna A, N'Guyen F, Plana M, Iruarrizaga E, Temam S, Even C, Ruiz EP, Bert M, Karamouza E, Thariat J, Kazmierska J, Psyrri A, Mesia R, Tao Y. Bourhis J, et al. Among authors: daste a. Lancet. 2025 Dec 22:S0140-6736(25)01850-1. doi: 10.1016/S0140-6736(25)01850-1. Online ahead of print. Lancet. 2025. PMID: 41448222
Immune checkpoint inhibitors and elderly people: A review.
Daste A, Domblides C, Gross-Goupil M, Chakiba C, Quivy A, Cochin V, de Mones E, Larmonier N, Soubeyran P, Ravaud A. Daste A, et al. Eur J Cancer. 2017 Sep;82:155-166. doi: 10.1016/j.ejca.2017.05.044. Epub 2017 Jul 6. Eur J Cancer. 2017. PMID: 28689093 Review.
Management of Immune Checkpoint Inhibitor Toxicities.
Durrechou Q, Domblides C, Sionneau B, Lefort F, Quivy A, Ravaud A, Gross-Goupil M, Daste A. Durrechou Q, et al. Among authors: daste a. Cancer Manag Res. 2020 Sep 28;12:9139-9158. doi: 10.2147/CMAR.S218756. eCollection 2020. Cancer Manag Res. 2020. PMID: 33061607 Free PMC article. Review.
Étude multicentrique de l'histologie des masses résiduelles des tumeurs germinales après chimiothérapie : existe-t-il des facteurs prédictifs ?
Dusaud M, Rivoire M, Bayoud Y, Sèbe P, Malavaud B, Daste A, Dariane C, Pignot G, Thoulouzan M, Bosset P, Safsaf A, Rigaud J, Houlgatte A, Durand X. Dusaud M, et al. Among authors: daste a. Prog Urol. 2014 Nov;24(13):864. doi: 10.1016/j.purol.2014.08.179. Epub 2014 Oct 30. Prog Urol. 2014. PMID: 26461704 French. No abstract available.
Targeted therapy and elderly people: A review.
Daste A, Chakiba C, Domblides C, Gross-Goupil M, Quivy A, Ravaud A, Soubeyran P. Daste A, et al. Eur J Cancer. 2016 Dec;69:199-215. doi: 10.1016/j.ejca.2016.10.005. Epub 2016 Nov 15. Eur J Cancer. 2016. PMID: 27855351 Review.
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).
Galot R, Le Tourneau C, Licitra L, Guigay J, Kong A, Tinhofer I, Even C, Daste A, Henry S, Borel C, Abdeddaim C, Seront E, Prevost JB, Rutten A, Saada-Bouzid E, Rolland F, Bonomo P, Rasschaert M, Dirix L, Olungu C, Tsechilidou K, Govaerts AS, Fortpied C, Joaquim A, Machiels JP. Galot R, et al. Among authors: daste a. ESMO Open. 2025 May;10(5):104554. doi: 10.1016/j.esmoop.2025.104554. Epub 2025 Apr 30. ESMO Open. 2025. PMID: 40311183 Free PMC article. Clinical Trial.
62 results